164 related articles for article (PubMed ID: 32389219)
1. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
2. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
[TBL] [Abstract][Full Text] [Related]
3. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.
Trosman JR; Weldon CB; Kelley RK; Phillips KA
J Natl Compr Canc Netw; 2015 Mar; 13(3):311-8. PubMed ID: 25736008
[TBL] [Abstract][Full Text] [Related]
4. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.
Trosman JR; Weldon CB; Gradishar WJ; Benson AB; Cristofanilli M; Kurian AW; Ford JM; Balch A; Watkins J; Phillips KA
Value Health; 2018 Sep; 21(9):1062-1068. PubMed ID: 30224110
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment and private payers's coverage of personalized medicine.
Trosman JR; Van Bebber SL; Phillips KA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP53-60. PubMed ID: 21711078
[TBL] [Abstract][Full Text] [Related]
6. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
7. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
8. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
[TBL] [Abstract][Full Text] [Related]
9. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?
Phillips KA
JAMA; 2018 Jun; 319(23):2379-2380. PubMed ID: 29710095
[No Abstract] [Full Text] [Related]
10. Private payers disagree with Medicare over medical device coverage about half the time.
Chambers JD; Chenoweth M; Thorat T; Neumann PJ
Health Aff (Millwood); 2015 Aug; 34(8):1376-82. PubMed ID: 26240252
[TBL] [Abstract][Full Text] [Related]
11. Clinical integration of next generation sequencing: coverage and reimbursement challenges.
Deverka PA; Dreyfus JC
J Law Med Ethics; 2014; 42 Suppl 1(Suppl 1):22-41. PubMed ID: 25298289
[TBL] [Abstract][Full Text] [Related]
12. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
[TBL] [Abstract][Full Text] [Related]
13. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
Trosman JR; Weldon CB; Douglas MP; Kurian AW; Kelley RK; Deverka PA; Phillips KA
J Natl Compr Canc Netw; 2017 Feb; 15(2):219-228. PubMed ID: 28188191
[No Abstract] [Full Text] [Related]
14. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
15. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
16. Proposal for a national coverage determination for the treatment of varicose veins and venous disease due to disparate Centers for Medicare and Medicaid Services local coverage determination policies.
Welch HJ; Kabnick L; Vasquez MA; Monahan DL; Lurie F; Jacobowitz G
J Vasc Surg Venous Lymphat Disord; 2017 May; 5(3):453-459. PubMed ID: 28411715
[TBL] [Abstract][Full Text] [Related]
17. Strengthening Multipayer Collaboration: Lessons From the Comprehensive Primary Care Initiative.
Anglin G; Tu HA; Liao K; Sessums L; Taylor EF
Milbank Q; 2017 Sep; 95(3):602-633. PubMed ID: 28895218
[TBL] [Abstract][Full Text] [Related]
18. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.
Douglas MP; Parker SL; Trosman JR; Slavotinek AM; Phillips KA
Genet Med; 2019 Jan; 21(1):152-160. PubMed ID: 29997388
[TBL] [Abstract][Full Text] [Related]
19. Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015.
Desai NR; Bourdillon PM; Parzynski CS; Brindis RG; Spatz ES; Masters C; Minges KE; Peterson P; Masoudi FA; Oetgen WJ; Buxton A; Zipes DP; Curtis JP
JAMA; 2018 Jul; 320(1):63-71. PubMed ID: 29971398
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
